ChromoCure Cites Study Published in January 15th, 2010 Issue of Cancer Research as Further Validation of Aneuploidy Theory of Ca
2010年1月21日 - 3:33AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) -- The Company announces that
its long-held theory of cancer, aneuploidy, has been further
validated by a study published in the January 15, 2010 issue of
Cancer Research (Volume 70, Issue 2). Authors Cui, Borysova,
Johnson and Guadagno, affiliated (respectively) with the Department
of Molecular Oncology and Analytic Microscopy Core Facility, H. Lee
Moffitt Cancer Center and Research Institute and Cancer Biology
Graduate Program, University of South Florida, Tampa, Florida,
concluded that "Evidence is offered for the hypothesis that the
early, founding effects of B-Raf mutations on melanoma development
occur initially through aneuploidy, before the benefits of
activated B-Raf to transformed cell growth and survival can
accrue."
These findings, together with recently announced supporting
studies at the Mayo Clinic, have further validated the chromosomal
theory of cancer, a theory long championed by ChromoCure. Their
findings, which appear in the December 2009 issue of the journal
Cancer Cell along with an independent commentary on the discovery,
end a major controversy in the field of cancer research as to
whether aneuploidy is a cause or a consequence of cancer and
further proves the aneuploidy basis of cancer.
These ground breaking research publications have initiated
renewed interest in aneuploidy research and reinforced ChromoCure's
leading edge status. As recently announced, ChromoCure has
accelerated the implementation of the Therapy and Cure component of
ChromoCure's business plan and is reshaping other segments of its
Business Plan.
The company welcomes these corroborating research publications
and anticipates the announcement of important new initiatives.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems. The Company's proprietary ChromoCure CS200 Chromosomal
Scanner system measure the unique genomic characteristic found in
100% of all cancers and never found in normal cells. The Company
believes its technology has an effective accuracy of 100% for all
cancers at all stages. The Company believes its technology superior
and will become the worldwide gold standard for cancer detection,
therapy and cure research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
Contact: ChromoCure, Inc. www.ChromoCure.com info@chromocure.com
Tel 1.775.636.654
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Chromocure Inc (CE) (その他OTC): 0 recent articles
その他のChromoCure, Inc.ニュース記事